Pacific Biosciences of California, Inc.
Here’s whether Pacific Biosciences of California, Inc. (PACB) is worth buying in 2026 — based on weekly-updated price trend, RSI momentum, and return vs. the S&P 500. Our current read: Bearish.
Concerns: trading below the 200-day MA (long-term downtrend); below the 50-day MA (medium-term momentum negative); 50-day MA is falling (-2.34% over 10 days); rising volume on a downtrend (distribution, 1.23x avg). Currently 57.9% off its 52-week high. Score: -4/7.
PACB is trading below its 200-day MA ($1.68) — a key warning sign the longer-term trend is under pressure. An RSI of 33.9 sits in the neutral zone — momentum is neither stretched nor exhausted. The 1-year return of -6.5% compares to +20.4% for SPY (trailed the market by 26.9%). The current 57.9% drawdown from the 52-week high reflects elevated risk for momentum-based strategies.